Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: Pool-analysis of phase III randomized clinical trials

Abstract Objectives To compare the main efficacy and safety endpoints of the pivotal randomised clinical trials (RCTs) on venous thromboembolism (VTE) prevention after total hip (THR) or knee (TKR) replacement with the new oral anticoagulants (NAs) versus enoxaparin. Methods A pool-analysis of 10 RC...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thrombosis research 2012-08, Vol.130 (2), p.183-191
Hauptverfasser:	Nieto, José A, Espada, Noelia Garrido, Merino, Ricardo Guijarro, González, Timoteo Cámara
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anticoagulants - adverse effects Anticoagulants - therapeutic use Arthroplasty, Replacement, Hip - adverse effects Arthroplasty, Replacement, Knee - adverse effects Benzimidazoles - adverse effects Benzimidazoles - therapeutic use beta-Alanine - adverse effects beta-Alanine - analogs & derivatives beta-Alanine - therapeutic use Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Dabigatran Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous enoxaparin Enoxaparin - adverse effects Enoxaparin - therapeutic use Hematology, Oncology and Palliative Medicine Hemorrhage - chemically induced Humans major bleeding Medical sciences Morpholines - adverse effects Morpholines - therapeutic use new oral anticoagulants Orthopedic surgery prophylaxis Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyridones - adverse effects Pyridones - therapeutic use Rivaroxaban Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Thiophenes - adverse effects Thiophenes - therapeutic use Treatment Outcome venous thromboembolism Venous Thromboembolism - etiology Venous Thromboembolism - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!